RxDoctor Payments Data

Ionn Carlo Diaz, NP

Nurse Practitioner · Katy, TXNPI 1629603790

Payments from drug & device makers

$1,173in general payments, 2019–2025

Across 39 payments — averaging $30.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$220
  • Endo Pharmaceuticals Inc.$215
  • 180 Medical, Inc.$132
  • Neurocrine Biosciences, Inc.$85
  • Urovant Sciences Inc$54
  • Mylan Specialty L.p.$54
  • plus $413 from 13 others

What the payments were for

  • Food & beverage$1,10894%
  • Education$656%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,173 in reported general payments places this provider in the 80th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$112,136
Medicare patients
53
Services billed
1,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban134$41,154
JardianceEmpagliflozin94$29,308
FarxigaDapagliflozin Propanediol48$15,115
FycompaPerampanel18$13,222
XcopriCenobamate12$9,845
VeltassaPatiromer Calcium Sorbitex11$8,266
XareltoRivaroxaban23$6,921
Divalproex Sodium145$4,705
Atorvastatin Calcium286$3,680
DapagliflozinDapagliflozin Propanediol11$3,184
Levothyroxine Sodium263$3,019
Vancomycin HclVancomycin/Water For Inj (Peg)15$2,744
Lacosamide39$2,695
EnuloseLactulose98$2,680
Lantus SolostarInsulin Glargine,hum.Rec.Anlog77$2,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$41,154134 claims
AstraZenecaFarxiga$22$15,11548 claims
Johnson & JohnsonXarelto$30$6,92123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →